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ARTICLE OPEN
Exploring the impact of chronic obstructive pulmonary disease
(COPD) on diabetes control in diabetes patients: a prospective
observational study in general practice
Hilde D Luijks1, Wim JC de Grauw1, Jacobus HJ Bor1, Chris van Weel1,2, Antoine LM Lagro-Janssen1, Marion CJ Biermans1 and
Tjard R Schermer1
BACKGROUND: Little is known about the association between COPD and diabetes control parameters.
AIMS: To explore the association between comorbid COPD and longitudinal glycaemic control (HbA1C) and systolic blood pressure
(SBP) in a primary care cohort of diabetes patients.
METHODS: This is a prospective cohort study of type 2 diabetes patients in the Netherlands. In a mixed model analysis, we tested
differences in the 5-year longitudinal development of HbA1C and SBP according to COPD comorbidity (present/absent). We
corrected for relevant covariates. In subgroup effect analyses, we tested whether potential differences between diabetes patients
with/without COPD were modiﬁed by age, sex, socio-economic status (SES) and body mass index (BMI).
RESULTS: We analysed 610 diabetes patients. A total of 63 patients (10.3%) had comorbid COPD. The presence of COPD was not
signiﬁcantly associated with the longitudinal development of HbA1C (P= 0.54) or SBP (P= 0.33), but subgroup effect analyses
showed signiﬁcant effect modiﬁcation by SES (Po0.01) and BMI (P= 0.03) on SBP. Diabetes patients without COPD had a ﬂat SBP
trend over time, with higher values in patients with a high BMI. For diabetes patients with COPD, SBP gradually increased over time
in the middle- and high-SES groups, and it decreased over time in those in the low-SES group.
CONCLUSIONS: The longitudinal development of HbA1C was not signiﬁcantly associated with comorbid COPD in diabetes patients.
The course of SBP in diabetes patients with COPD is signiﬁcantly associated with SES (not BMI) in contrast to those without COPD.
Comorbid COPD was associated with longitudinal diabetes control parameters, but it has complex interactions with other patient
characteristics. Further research is needed.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is typically
diagnosed in middle-aged subjects who also have an increased
risk for other chronic conditions.1 The presence of other diseases
in addition to an ‘index disease’ is deﬁned as comorbidity.2
Among patients with mild-to-moderate COPD, the main causes of
death are comorbid diseases such as lung cancer and cardiovas-
cular diseases.3 COPD has a large impact on morbidity and
mortality.4
Another example of a chronic disease with marked effects on
global health and health care is type 2 diabetes.4,5 Of all patients
with COPD, 9–13% of the patients have comorbid diabetes,6–9 and
4–13% of patients with diabetes have comorbid COPD.9–11
Although these numbers originate from different studies and
consequently are not directly comparable, they clearly illustrate that
the combination of COPD and diabetes is a rather common one.
In recent years, knowledge and awareness of the importance of
patient-speciﬁc factors in the treatment of COPD12 and diabetes13
has grown, resulting in an increased tendency to individualise
disease management. An important characteristic of a patient with
a speciﬁc chronic disease, such as COPD, is the comorbidity that
may also be present. However, current guidelines for COPD and
diabetes have limited applicability for patients with comorbid
conditions.14 Very little is known on how the presence of a speciﬁc
disease, such as COPD, inﬂuences the long-term outcomes of
another disease, such as diabetes. This type of information is
important if health care professionals aim to personalise disease
management plans for COPD and diabetes patients. In addition,
other characteristics such as age, sex, body mass index (BMI) and
socio-economic status (SES) may have well-known effects on
COPD15–17 and on diabetes,18,19 but how they interact if both
diseases are present in one and the same patient is unknown.
Detailed data on comorbidity, patient characteristics and disease
control parameters from a representative patient population may
inform us about the interaction between the two diseases and the
impact on patients’ prognosis.
The aim of this explorative, hypothesis-generating paper was to
investigate the association between COPD as a comorbid
condition and longitudinal diabetes control parameters in patients
with type 2 diabetes in primary care. We also explored the role of
sex, age, BMI and SES in the relationship between COPD and
diabetes control.
MATERIALS AND METHODS
Design and study subjects
We used available data from a dynamic prospective cohort of diabetes
patients registered in the Continuous Morbidity Registration (CMR), a
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general practice registration network in the Nijmegen region, the
Netherlands. The four practices constituting the CMR have been recording
all morbidities that are presented to the general practitioners (GPs) on a
daily basis since 1967.20 The database reﬂects the health care system in the
Netherlands,21 where patients are registered with a general practice and
have access to specialist care through that practice. In this system, where
GPs receive capitation payment, the nature of medical conditions or
treatment does not inﬂuence the GPs’ performances. Details on the
composition of our diabetes cohort are described elsewhere.10 In short, we
included all adult patients with a new diagnosis of type 2 diabetes within
the observation period of the study (1 January 1985 to 31 December 2006).
Time from the start to the end of observation varied between patients,
beginning with either the start of the study period or the date of a
patient’s enrolment in a CMR practice. The observation period ended
either at the end of our study period or with a patient’s death or
deregistration from the practice.
All four CMR practices also participate in the so-called ‘Nijmegen
Monitoring Project’ (NMP),22 which was initiated in 1985 to systematically
record diagnostic and monitoring measurements of patients with diabetes
and/or hypertension. The NMP database includes demographic data,
physical diagnostics (e.g., blood pressure, weight, height) and laboratory
data (e.g., HbA1C, glucose levels). Monitoring data are collected by the GPs
and practice nurses during routine 3-monthly diabetes check-up visits for
all diabetes patients under GP care. The practices involved have been
shown to provide good-quality diabetes care.22 We linked data from these
two databases to study the effects of chronic comorbidity (data originating
from the CMR) on the course of diabetes control over time (data from the
NMP). The current paper presents results from the effect of COPD, as
selected comorbid disease, on longitudinal diabetes control parameters,
and effect modiﬁcation by a number of patient characteristics in subgroup
effect analyses. This analysis is part of a larger project studying the effects
of different types of comorbid diseases on diabetes control parameters.
The CMR and NMP registries comply with the Code of Conduct for
Health Research, which has been approved by the Data Protection
Authorities for conformity with the applicable Dutch privacy legislation. For
this study, approval of an ethics committee was not required.
Selection of COPD and other comorbidities
The presence of COPD was identiﬁed as a doctor diagnosis recorded in the
CMR database. The CMR has previously been used to study cohorts of
patients with COPD,23,24 and the diagnoses correlate well with spirometry
results.25 Details on the recording of comorbidity have been reported in a
previous paper.10 We selected comorbid COPD as a single disease of
particular interest for the analysis of possible associations between
comorbid conditions and the course of diabetes control parameters, and
we were, in addition, interested especially in comorbid malignancies and
cardiovascular, mental and musculoskeletal diseases.
Study outcomes
HbA1C (in %, the current unit during our study period) and systolic blood
pressure (SBP, in mmHg) were the primary study outcomes. Measurement
of HbA1C is performed at the annual check-up visits. Blood pressure
measurement is generally performed at every check-up visit. To include
patients with sufﬁcient follow-up starting from the diagnosis, we only
included patients with their ﬁrst measurement performed within the ﬁrst
4 months after the diabetes diagnosis and labelled these as ‘baseline
measurements’. All subsequent measurements were regarded as repeated
measurements for individual patients and contributed to the longitudinal
analysis. We studied the development of these outcomes during the 5-year
follow-up.
Statistical analysis
SPSS (version 20.0) and SAS (version 9.02) software supported the analysis.
Characteristics of the study population are provided using descriptive
statistics. We compared linear trends for both HbA1C and SBP in the 5 years
after the diabetes diagnosis between patients with and patients without
comorbid COPD. We applied a random intercept mixed model analysis
using measurements nested within patients.26 In this model, the presence
of existing COPD, i.e., recorded before the diabetes diagnosis, was the
variable of interest. We added an interaction term ‘time’ by ‘COPD’ (absent/
present) to the model to explore differences in HbA1C and SBP trends
according to the absence or presence of COPD. In this comparison
between patients with and without COPD, we entered sex, age at diabetes
diagnosis, SES, BMI (handled as ‘last observation carried forward’26) and the
presence of other comorbidities (as speciﬁed above) as potential
confounders. Values for age and BMI were handled as continuous variables
in the mixed model, but we categorised them as ‘low’, ‘intermediate’ and
‘high’ values to facilitate (graphical) presentation of the results. The
categorisation was based on the limits of the ﬁrst, second (i.e., the median)
and third quartiles of the distribution of age and BMI values of the patients
who contributed to the analysis.
Furthermore, we performed subgroup effect analyses to test whether
potential differences in the HbA1C and SBP trends between diabetes
patients with or without comorbid COPD were modiﬁed by sex, age, SES or
BMI. The confounders in the initial analysis were now tested for potential
effect modiﬁcation separately by adding an interaction term ‘time’ by
‘COPD’ (absent/present) by ‘potential effect modiﬁer’ to the model.
Nonsigniﬁcant interaction terms were removed in a stepwise backward
elimination procedure.26 In these subgroup effect analyses, we added the
presence of other comorbidities as potential confounders (not as potential
effect modiﬁers). In cases in which no signiﬁcant results arose from the
subgroup effect analysis, the ﬁrst model (without subgroup effect analysis)
deﬁned the results.
Not only comorbid COPD already present at the study start may be
associated with the longitudinal diabetes outcomes, the same may be the
case for incident COPD after the patient’s diabetes diagnosis. Therefore, we
performed sensitivity analyses excluding the patients who did not have
COPD at their diabetes diagnosis date but who were diagnosed with COPD
during the 5-year follow-up.
A P-value o0.05 was considered statistically signiﬁcant.
New diagnosis of type 2 diabetes
in CMR practice between
1985–2006:
n = 714  
HbA1C and SBP unavailable:
n = 30
HbA1C and/or SBP available1:
n = 684 
No ‘baseline measurement’2
available:
n = 74 
‘Baseline measurement’ available
(included for longitudinal
analysis):
n = 610  
Patients without pre-existent
comorbid COPD
n = 547 
Patients with pre-existent
comorbid COPD:
n = 63  
Patients with incident comorbid
COPD during 5 years of follow-up
n = 8  
Figure 1. 1Patients with the GP responsible for diabetes treatment.
2A patient’s ﬁrst outcome measurements collected from a diabetes
check-up visit within the ﬁrst 4 months since the diabetes diagnosis
was labelled as ‘baseline measurement’. CMR, Continuous Morbidity
Registration; COPD, chronic obstructive pulmonary disease; GP,
general practitioner; SBP, systolic blood pressure.
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RESULTS
Study subjects and baseline characteristics
Figure 1 shows a ﬂowchart of our study population. We included
610 patients with a mean age of 63 years (s.d. 12.5, Table 1) for
longitudinal analysis. In all, 63 patients (10.3%) had comorbid
COPD at the date of their diabetes diagnosis, and another 8
patients were diagnosed with COPD during the 5-year follow-up
period. Patients with pre-existing COPD were older and had more
additional comorbid conditions, apart from COPD, compared with
patients without COPD (i.e., musculoskeletal disease, 51 vs. 30%).
Note that in the longitudinal analyses we corrected for the
presence of selected comorbidity.
Inﬂuence of comorbid COPD on the course of HbA1c and SBP
After correction for covariates, comorbid COPD was not signiﬁ-
cantly associated with the course of HbA1C (P= 0.54) or SBP
(P= 0.33) values over time in the initial analyses. Figure 2 shows
the time trends for patients with and without comorbid COPD and
the additional effects of covariates. The ﬁgure footnotes provide
information for the deﬁnition of the ‘reference category’.
In the subgroup effect analyses, however, we found a
statistically signiﬁcant association between comorbid COPD and
the course of SBP, with effect modiﬁcation of SES (Po0.01)
and BMI (P= 0.03). To express these complex ﬁndings in a
comprehensible way, Figure 3 shows a graphical representation of
the direction of effects, with separate graphs for combinations of
SES and BMI. The ﬁgure shows that in the absence of COPD (blue
lines), longitudinal SBP values are relatively stable over time, with
higher values when BMI is higher (compare panels a, c and e).
Diabetes patients with comorbid COPD (red lines) showed a more
variable course of SBP over time, with SES more than BMI deﬁning
the direction of effects and absolute SBP values. Note that, in the
subgroup effect analysis, nonsigniﬁcant terms were removed from
the model; i.e., all variables presented contributed signiﬁcantly to
the model predicting the outcome. Age (Po0.01), presence of
comorbid mental (P= 0.03) and comorbid cardiovascular disease
(Po0.01) had additional effects on the subgroup effect analysis
results (not dependent on the presence or absence of comorbid
COPD, additional effects). Absolute values depended on the mix of
patient characteristics. No signiﬁcant effect modiﬁcation was
found from any of the deﬁned subgroups on the longitudinal
development of HbA1C in the presence of comorbid COPD.
Sensitivity analysis
After exclusion of cases with incident COPD during the 5-year
follow-up period, we did not observe a signiﬁcantly different
association between COPD and HbA1C (P= 0.54) or SBP (P= 0.34),
nor did we observe signiﬁcant differences in the results from the
subgroup effect analyses.
Table 1. Baseline characteristics of patient population, according to the presence/absence of COPD
Total included n= 610 COPD presenta n= 63 COPD absenta n= 547 P-valuea
Patient characteristics
Sex: male, n (%) 294 (48.2) 34 (54.0) 260 (47.5) 0.33
Age at DM diagnosis, years; mean (s.d.) 63.0 (12.5) 69.0 (11.0) 62.3 (12.5) o0.001
Follow-up time, years; mean (s.d., range) 6.2 (4.6; 0.1–21.9) 4.1 (3.6; 0.3–15.6) 6.5 (4.7; 0.1–21.9) o0.001
Measurements per patient, total number, mean
(median; s.d.; range)
21.8 (17.5; 18.2; 1–106) 15.7 (10; 14.9; 1–86) 22.5 (19; 18.4; 1–106) 0.001
BMI at baselineb, mean (s.d.), kg/m2 29.8 (5.1) 29.5 (5.2) 29.8 (5.1) 0.57
SESb, n (%)
Low 315 (52.1) 37 (58.7) 278 (51.3) 0.26
Middle 242 (40.0) 24 (38.1) 218 (40.2)
High 48 (7.9) 2 (3.2) 46 (8.5)
Year of diabetes diagnosis, n (%)
1985–1989 83 (13.6) 3 (4.8) 80 (14.6) 0.07
1990–1999 235 (38.5) 24 (38.1) 211 (38.6)
2000–2006 292 (47.9) 36 (57.1) 256 (46.8)
Comorbidity data
Comorbid diseasesc, mean number (s.d.; range) 2.7 (2.3; 0–11) 4.0 (2.5; 0–11) 2.6 (2.2; 0–11) o0.001
Comorbid diseasesc, (categorised), n (%)
0 100 (16.4) 4 (6.3) 96 (17.6) 0.002
1 or 2 227 (37.2) 17 (27.0) 210 (38.4)
3 and more 283 (46.4) 42 (66.7) 241 (44.1)
Cardiovascular comorbidityc, present, n (%) 390 (63.9) 44 (69.8) 346 (63.3) 0.30
Musculoskeletal comorbidityc, present, n (%) 197 (32.3) 32 (50.8) 165 (30.2) 0.001
Mental comorbidityc, present, n (%) 140 (23.0) 18 (28.6) 122 (22.3) 0.26
Comorbid malignancyc, present, n (%) 42 (6.9) 4 (6.3) 38 (6.9) 0.86
Incident comorbid COPD after DM diagnosisd, n (%) 12 (2.0) NA 12 (2.2) NA
Incident COPD in the ﬁrst year after DM diagnosis, n (%) 1 (0.2) NA 1 (0.2) NA
Incident COPD in the ﬁrst 5 years after DM diagnosis, n (%) 8 (1.3) NA 8 (1.5) NA
Characteristics of patients at baseline, i.e., at the date of the diabetes diagnosis.
Abbreviations: BMI, body mass index; DM, type 2 diabetes mellitus; NA, not applicable; SES, socio-economic status.
aCOPD presence/absence: assessed on the date of diabetes diagnosis. P-values displayed are calculated for the difference between the group with versus
without comorbid COPD. We performed Chi-square tests for continuous variables and independent t-tests for continuous variables. P-values o0.05 were
considered statistically signiﬁcant.
bNumber of measurements available for BMI at baseline: 576 (missing at baseline: n= 34). Number of measurements available for SES at baseline: 605 (missing
at baseline: n= 5).
cPresence of any type of comorbid disease was assessed at the date of diabetes diagnosis. For the diabetes patients with comorbid COPD present at the
diabetes diagnosis date, we excluded COPD in the count of the total number of comorbid diseases to make a meaningful comparison with the total number of
comorbid diseases in patients without COPD.
dMean time (after the diabetes diagnosis date) until the date of comorbid COPD diagnosis, for incident cases, is 4.6 years.
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DISCUSSION
Main ﬁndings
In the current study, we explored the association between
comorbid COPD and the longitudinal development of HbA1C
and SBP in a representative cohort of newly diagnosed type 2
diabetes patients in primary care during 5 years of follow-up. The
initial analyses showed no signiﬁcant associations between COPD
and these outcomes, but subgroup effect analysis indicated that,
in the presence of COPD, the development of SBP was different for
patients from different SES and BMI subgroups. This suggests that
comorbid COPD, in relation with these particular patient
characteristics, may inﬂuence long-term diabetes control
parameters.
Strengths and limitations of this study
In this dynamic cohort study, we used data from robust datasets
that originate from decades of experience in morbidity recording
in a practice-based research network from our department20
and good quality of diabetes care.22 We studied relevant
diabetes control parameters as study outcomes (not ‘treatment
intensiﬁcation’27,28) over a follow-up period that was long enough
to assess potential associations with comorbid COPD. Comparison
of outcomes over time between patients was meaningful, as we
included only newly diagnosed diabetes patients. Another
strength is that we studied an unselected population with ‘real
patients’ receiving regular primary health care, i.e., a representa-
tive sample of the type 2 diabetes patient population.
It is important to realise that, within our study period, the
criteria for the diagnosis of COPD and diabetes have changed. The
current criteria for diagnosing COPD were introduced in Dutch
general practice in 2001.29 Towards the end of our observation
period, there was a higher rate of diabetes diagnoses.30 This
implies that COPD and diabetes data from early in the observation
period may not be fully comparable to similar data at the end of
the period. This type of limitation is inherent to working with
longitudinal data. In general, the CMR has shown to record
diagnoses with high validity.31
One limitation of this study is that we were unable to account
for smoking in the analyses, because this has not been
consistently recorded in the CMR and NMP databases, nor did
we have data available on the severity of COPD (i.e., degree of
airﬂow obstruction, exacerbation rate, severity of dyspnoea). From
a previous study, we know that the majority of COPD patients in
the NMP registry have mild or moderate COPD,25 but from our
current work we cannot tell whether and how the severity of
underlying COPD may be associated with the course of diabetes
outcomes.
Clearly, the development of HbA1C and SBP over time as
observed will have been inﬂuenced by the diabetes treatment as
provided by GPs. This treatment may include stimulation of
physical exercise (which is beneﬁcial not only for the diabetes but
also for the COPD) and prescription of glucose-lowering
medication.32 Medication prescribed for COPD (e.g., oral or
inhaled corticosteroids) may increase the glucose level and SBP
in patients with diabetes.33,34 In this dynamic cohort study, it was
Figure 2. Mixed model results (no subgroup effect analysis): longitudinal HbA1C (a) and SBP (b) outcomes of diabetes patients with and
without comorbid COPD. Comorbid diseases: absence and presence are assessed on the date of diabetes diagnosis. Number (n) of cases with
completed longitudinal analysis (no missing data on any of the variables included in the mixed model throughout): 582. Cases with missing
values for BMI: n= 23, cases with missing values for SES: n= 5. *P-values o0.05. Age and BMI categories: based on the distribution of age and
BMI values of patients contributing to the analyses, limits for ‘low’, ‘intermediate’ and ‘high’ values were 54, 64 and 72 years for age, and 26.0,
28.5 and 31.8 kg/m2 for BMI, respectively. Graphs for ‘reference categories’: in the graphic presentation, graph lines represent HbA1C or SBP
courses for speciﬁc patient variables—for example, a male patient from the low-SES group with a speciﬁc age and BMI. We deﬁne the
(theoretical) combination of the patient characteristics ‘male sex, low SES, median age, median BMI and absence of other comorbidity’ as
‘reference category’. The ‘Additional effects table’ below each graph contains information needed to construct lines of predicted outcomes,
based on the mixed model results, for other subjects than the ‘reference category’. It shows the additional effects (to be added to the graphs
displayed above) for other covariates included in the model. These values are not time dependent and not dependent on the absence or
presence of COPD. Example: HbA1C courses over time for patients with and without comorbid COPD are shown in a. The ‘Additional effects
table’ shows an additional effect of +0.04 (% HbA1C) for female sex. This means 0.04 should be added to the blue line for female patients
without COPD and 0.04 should be added to the red line for female patients with COPD. The P-value of 0.70 shows that this additional effect of
sex on HbA1C in this analysis is not statistically signiﬁcant. BMI, body mass index; COPD, chronic obstructive pulmonary disease; SBP, systolic
blood pressure; SES, socio-economic status.
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not possible to compare therapeutic regimes between diabetes
patients with and without COPD. Differences in medication or
lifestyle regimes may have contributed to the observed
differences.
Twenty-eight cases with missing data for SES or BMI throughout
the follow-up period (variables included in the linear model)
dropped out. Their numbers were relatively low, which makes it
unlikely that they introduced bias.
The percentage of diabetes patients with comorbid COPD in our
cohort corresponds with prevalence numbers described in the
literature.9–11 Although the absolute number of patients with
COPD (n= 63) was relatively low, one of the subgroup effect
analyses did show signiﬁcant results. In a larger sample of diabetes
patients with comorbid COPD, it would have been possible that
some nonsigniﬁcant trends observed would have reached
statistical signiﬁcance.
The current paper is one result of a larger project with an
explorative design aimed at investigating associations between
several types of comorbidities on diabetes control parameters.
These results generate new hypotheses and may guide further
research elaborating on the early ﬁndings. It helps increase the
evidence base for the complex care to patients with multi-
morbidity. We believe that the most important strength of the
current work is precisely this novelty. To the best of our
knowledge, this is the ﬁrst study exploring longitudinal associa-
tions between COPD and another common chronic disease, in this
case diabetes. Because the combined occurrence of diabetes and
COPD is common, assessing possible interactions in terms of
long-term outcomes is important. Our observation that,
in some subgroups, comorbid COPD was associated with altered
diabetes outcomes warrants further research in this area.
Our study may serve as an example of how to investigate the
complex relationships between two or more chronic conditions
(i.e., multimorbidity) on patients’ prognoses for the diseases
involved.
Interpretation of ﬁndings in relation to previously published work
The unfavourable effect of increasing BMI on systolic blood
pressure is not surprising.35 Our observations indicate that for
diabetes patients with comorbid COPD, patient characteristics that
predict long-term outcomes may be different from those without
COPD. Our study design had an explorative nature in which we
tested several associations; hence, care needs to be taken in the
interpretation of our ﬁndings. We did not ﬁnd signiﬁcant
associations between comorbid COPD and all study outcomes
tested. It is possible that the signiﬁcant associations between
longitudinal SBP and comorbid COPD among diabetes patients
may not be replicated in a future study. It cannot be concluded
from observational research only whether and how our ﬁndings
should be translated into therapeutic consequences. One could
reason that, in patients with diabetes and comorbid COPD, factors
related to a patient’s SES are more important in achieving long-
term SBP control than just reducing BMI. Our ﬁnding that among
COPD patients the lower SES group had the best long-term SBP
Figure 3. Mixed model results for subgroup effect analysis: 5-year course of SBP for diabetes patients with and without comorbid COPD,
modiﬁed by SES (Po0.01) and BMI (P= 0.03). The explanations are the same as Figure 2. Graphs are shown for the ‘reference category’
(i.e., male sex, median age, absence of other comorbidity), but SES and BMI vary as speciﬁed in the ﬁgure. BMI, body mass index; COPD,
chronic obstructive pulmonary disease; SBP, systolic blood pressure; SES, socio-economic status.
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control is surprising, but this ﬁnding would ﬁrst need to be
conﬁrmed in a larger study before we should speculate about
possible explanations. In our cohort, diabetes patients with
comorbid COPD had different (comorbidity) characteristics than
those without COPD—an important notion for the treatment of
patients with either or both of these diseases. The observed
differences may result from disease-speciﬁc or from generic
factors such as obesity, lifestyle and smoking. The need for more
research aiming at profoundly investigating the associations
between COPD, SES and diabetes control parameters is obvious.
Previous studies described negative associations between low SES
and COPD36 and diabetes19 prognosis. Studies reporting on the
relationship between SES and prevalence of multimorbidity in
general described negative associations.37–39 We have not been
able to trace any previously published papers paying attention to
the role of SES in relation to the speciﬁc combination of COPD and
diabetes.
After the ﬁrst recognition of the importance of lipid regulation
in diabetes,40 the revised version of the Dutch College of General
Practitioners diabetes guideline in 1999 resulted in increased
attention to the role of lipids halfway through our study period.
For this reason, and as studying one glycaemic and one non-
glycaemic control parameter already resulted in a large data set
with many associations tested, we decided not to include lipids as
diabetes control parameters.
Some covariates showed signiﬁcant additional effects, both on
the nonsigniﬁcant results from the initial models and on the
signiﬁcant subgroup effect analysis results. Note that these are
independent from time and from the presence/absence of COPD.
Augmenting effects from increasing BMI and age (on both study
outcomes) and from comorbid cardiovascular disease (on SBP) can
be expected among diabetes patients. We assume that the
consistent diminishing effect of comorbid mental diseases is
related to a higher consultation frequency among these
patients,41 offering more opportunities to diagnose and manage
diabetes (or hypertension) in an early stage, resulting in slightly
better outcomes.
Pathophysiologic mechanisms that have been suggested to
have a role in the relationship between respiratory impairment in
COPD patients and diabetes include an increased BMI, altered
respiratory compliance, weakness of the respiratory muscles or
neuropathies.7
GPs’ beliefs about the feasibility and beneﬁts of medication
regimes may be inﬂuenced by the presence of comorbidity,42–44
which might result in deliberate ﬂexible medication prescriptions
in patients with comorbidities. Given these considerations, we
believe that the absence of an association between comorbid
COPD and long-term HbA1C outcomes among diabetes patients
implies that GPs responsible for treatment provide good-quality
diabetes care despite the presence of comorbidities such as COPD.
Implications for future research, policy and practice
The current study provides novel observational data in a research
area that is still underdeveloped, i.e., multimorbidity. It focuses on
the impact of COPD as a comorbid disease in patients with
diabetes. Comorbidity should be regarded as a patient character-
istic that may inﬂuence relevant outcomes of another disease.
Instead of focussing mainly on disease-speciﬁc outcomes, future
research should pay more attention to the effects of comorbidity
and other patient characteristics such as socio-demographic
background.
Moreover, future work may study the effects of (other) incident
comorbidity on diabetes outcomes in more detail. Further
investigations of potential associations between diabetes, and
other prevalent chronic diseases, with relevant COPD outcomes
are desired too, as well as other combinations of diseases.
The majority of practitioners caring for patients with either
COPD or diabetes will see several patients with these diseases
combined, and our ﬁndings may help raise awareness on the
importance of formulating personalised management plans that
aim for sensible outcomes taking into account both diseases. The
current explorations do not yet allow for concrete recommenda-
tions for daily practice changes—our ﬁndings need to be
replicated in larger diabetes cohorts.
Knowledge of the impact of comorbidity on disease outcomes
is also important to support pay-for-performance initiatives that
facilitate patient-centred care. Therefore, ongoing research in this
area should be prioritised by funding bodies and policymakers.
Conclusions
Comorbid COPD was associated with longitudinal control para-
meters of newly diagnosed type 2 diabetes patients in general
practice. This association was observed on SBP (but not on HbA1C)
and was modiﬁed by SES and BMI. Although these results need to
be veriﬁed ﬁrst, this exploratory study provides new information
on the interaction between multiple chronic diseases, and may
guide further development of personalised care that accounts for
patients’ comorbidity.
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